Sixty-two adults underwent marrow or blood stem cell transplantation from an HLA-matched related donor using high-dose thiotepa, @entity1863 , and @entity786 (TBC) as the preparative regimen for treatment of advanced @entity2590 ( @entity2590 ) ( @entity417 with excess blasts with or without transformation) or @entity3052 ( @entity3052 ) past first remission. All evaluable @entity1 engrafted and had complete donor chimerism. A grade 3-4 regimen-related @entity137 occurred in eight (13%) @entity1 , and a diagnosis of @entity2590 was the only independent risk factor for grade 3-4 regimen-related @entity137 (hazard ratio 9.25, P = 0.01). Day-100 treatment-related mortality (TRM) was 19%. Poor-prognosis cytogenetics increased the risk of day-100 TRM (hazard ratio 11.4, P = 0.003), and use of @entity1140 for graft-versus-host disease prophylaxis reduced the risk of day-100 TRM (hazard ratio 0.13, P = 0.027). For all @entity1 , the three-year relapse rate was 43% (95% CI, 28%-58%). Refractoriness to conventional induction chemotherapy prior to transplantation was an independent risk factor for relapse (hazard ratio 10.8, P = 0.02). Three-year survival was 26% (95% CI, 14%-37%); survival rates were 29% for those transplanted for @entity3052 in second remission, 31% transplanted for @entity3052 in relapse, and 17% with @entity2590 , and there were no independent risk factors for survival. TBC is an active preparative regimen for advanced @entity3052 . @entity1 with advanced @entity2590 appeared to have a higher risk of @entity137 and early mortality, and alternative preparative regimens should be considered for these @entity1 .

Thiotepa, @entity1863 , and @entity786 as a preparative regimen for allogeneic transplantation for advanced @entity2590 and XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity417 :: ('MESH:D000740', 'Disease') :: ['refractory anemia'] @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplastic syndrome', 'MDS'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myelogenous leukemia', 'AML'] @entity1863 :: ('MESH:D002066', 'Chemical') :: ['busulfan'] @entity1140 :: ('MESH:D016559', 'Chemical') :: ['tacrolimus']
@entity3052 :: (MESH:D015470,Disease) :: ['acute myelogenous leukemia']
